Dannah Raz, MD, MPH, Named to Modern Healthcare’s 40 Under 40 - Scorecard - MDSpire

Dannah Raz, MD, MPH, Named to Modern Healthcare’s 40 Under 40

Phoenix Children’s, one of the top-ranked pediatric health systems in the West, announced that Dannah Raz, MD, MPH, division chief of developmental and behavioral pediatrics, has been named to Modern Healthcare’s 40 Under 40 for 2026

  • April 9, 2026

  • 3 min

Share

Clinical Scorecard: Dannah Raz, MD, MPH, Named to Modern Healthcare’s 40 Under 40

At a Glance

CategoryDetail
ConditionDevelopmental and Behavioral Pediatrics
Key MechanismsTeam-based workflows, cross-division collaboration, multidisciplinary care models
Target PopulationChildren with neurodevelopmental disabilities
Care SettingPediatric health systems

Key Highlights

  • Dannah Raz recognized in Modern Healthcare’s 40 Under 40 for 2026
  • 20% reduction in wait times for autism evaluations for children ages four and younger
  • Established one of Arizona’s only multidisciplinary Down syndrome clinics
  • Launched a national autism education summit
  • Implemented care navigation services to improve post-diagnosis support

Guideline-Based Recommendations

Diagnosis

  • Enhance early diagnosis for developmental needs

Management

  • Utilize multidisciplinary care models for comprehensive treatment

Monitoring & Follow-up

  • Track improvements in access and coordination of care

Risks

  • Barriers to access for families needing developmental support

Patient & Prescribing Data

Families of children with developmental disabilities

Focus on reducing wait times and improving access to care

Clinical Best Practices

  • Foster collaboration across specialties and community partners
  • Implement team-based workflows for efficiency
  • Provide ongoing education and support for families

Related Resources & Content

Original Source(s)

Dannah Raz, MD, MPH, Named to Modern Healthcare’s 40 Under 40

  • April 9, 2026

Related Content

Medical Oddities: Gummies Good for the Gums

From gummies to hookworms, trackers to vibrating pills, medicine took some unexpected turns this week.

FDA Expands CAPVAXIVE Pediatric Use

Phase 3 data showed noninferior immune responses vs pneumococcal 23-valent polysaccharide vaccine in pediatric patients at increased risk.

10 CMS and FDA Actions Affecting Care in 2026

From Medicare payment updates to drug approvals and device access, these federal actions may affect reimbursement, prescribing, patient access, and clinical workflows.